Orthocell Limited (ASX:OCC) Managing Director, Paul Anderson presents on advances in regenerative medicine, the company's product line up and commercialisation at FNN's Investor Event.
- Relatively new field of medicine that seeks to repair injured or diseased tissue by harnessing the body’s own regenerative capabilities
- CelGro Soft tissue reconstruction platform medical device
- Ortho-ATI regeneration of tendons cell therapy
- Large unmet clinical need
- Optimised manufacturing capability
- Ageing population and rising musculoskeletal disorders
- Demand for safe, efficient and cost effective treatments
For more information, watch Managing Director, Paul Anderson present.